Table 5.
Pharmacokinetic parameters for HBK-14 (2.5 mg/kg) and HBK-15 (1.25 mg/kg) after i.v. and i.p. administrations
| Parameters | HBK-14 | HBK-15 | ||
|---|---|---|---|---|
| i.v. | i.p. | i.v. | i.p. | |
| C 0 [ng/mL] | 410 | – | 602 | – |
| AUC0→∞ [ng min/mL] | 103,499 | 33,617 | 29,018 | 15,683 |
| MRT [min] | 454.1 | 48.3 | 90.2 | 108.7 |
| t 0.5 [min] | 322.7 | 38.2 | 70.5 | 83.5 |
| C max [ng/mL] | – | 269.3 | – | 359 |
| t max [min] | – | 5 | – | 5 |
| V d [L/kg] | 11.2 | – | 3.5 | – |
| Cl [mL/min/kg] | 24.2 | – | 40.2 | – |
| F [%] | 15 | 54 | ||
Twenty-eight adult male mice (CD-1, 20–25 g) were used in the study
C 0 the initial concentration, C max the maximum plasma concentration, t max time to reach the maximum plasma concentration, t 0.5 terminal half-life, MRT mean residence time, AUC 0→∞ area under the concentration–time curve from zero up to infinitive time, Cl systemic clearance, V d volume of distribution at steady state, F absolute bioavailability, i.v. intravenous, i.p. intraperitoneal